NDAOTICSOLUTION/DROPS
Approved
Feb 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIDESILON is a combination otic solution containing glacial acetic acid and desonide (a mild corticosteroid) approved in 1978 for treatment of ear infections and inflammation. The acetic acid provides antimicrobial properties while desonide reduces inflammation in the external auditory canal. It is administered as ear drops for localized otic disease.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely focused on cost management and defensive positioning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TRIDESILON offers limited growth opportunity but provides valuable experience in mature product management, generic defense strategies, and legacy brand optimization. Roles focus on profitability, compliance, and managed decline rather than innovation.
Brand ManagerProduct Manager
Worked on TRIDESILON at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.